JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

4小时前 jolin_story_47656629 来自云南省

3-30投稿，4-5under review，4-24 with editor，希望有revise

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2024-01-16 ms8000001820221539 来自湖南省

审稿速度:1.0
偏重的研究方向：代谢内分泌
经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀

140 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2021-03-02 延光星辰

2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷

767 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2024-03-27 ms8000000183026287 来自山东省

审稿速度:3.0 | 投稿命中率:25.0
经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊

87 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2022-08-26 ms5000000174582530

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：心血管;糖尿病
经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！

479 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2019-05-27 lucifer11

审稿速度:3.0
经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。

154 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2021-09-25 ms2000000907990850

审稿速度:1.0
经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。

674 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2024-01-24 ms6000000741257643 来自广西

不能提供中文的伦理，不懂怎么搞

139 0

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2023-06-24 MedSci_007 来自吉林省

第一天投稿，第二天under review，第四天with editor。。。。

255 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2200334, encodeId=be5122003344b, content=3-30投稿，4-5under review，4-24 with editor，希望有revise, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7bfb2469150, createdName=jolin_story_47656629, createdTime=Thu Apr 25 12:38:44 CST 2024, time=4小时前, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0 偏重的研究方向：代谢内分泌 经验分享：1.9号投的稿，已经过去7天了，一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿，一审3个月，催稿问了下，说是前两个审稿人意见有分歧，所以邀请了第三个审稿人；返回大修2个月；2021.02.04再投，目前with editor了，希望能接收，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3月18日投稿，到现在一直是 Manuscript Submitted！什么情况，我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：记录一下，第一个SCI：5月10日投稿的，大约5天内就被under review被送审了。一个月后返回。修稿一个月后，两周就接受啦。审稿速度非常可！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571551, encodeId=a9d65e155113, content=审稿速度:3.0 经验分享：于2019年2月26日投稿，一篇meta，然后5月18日直接被拒，三个月啊。编者的建议主要是我纳入的中文文献库（CNKI和万方），他们无法重复。所以纳入中文文献的meta慎投这个杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0icicabQPFRfglHZr0mpDfC2oYjwL5n0xDc0wODUNEyWJuia9wXP3TnHwrZMktLMl7OQH7ZoUicGQHiclLb373GdibAg/132, createdBy=b44f2541766, createdName=lucifer11, createdTime=Mon May 27 16:57:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054662, encodeId=43b91054662ed, content=审稿速度:1.0 经验分享：一审一个月，两个审稿人，提的问题都很友善，提交返修后两周接收。补充材料需要上传至公共数据库并且在文中引用（第一次投稿时可以不上传）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=674, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6ec5497373, createdName=ms2000000907990850, createdTime=Sat Sep 25 10:21:26 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理，不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿，第二天under review，第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省)]

2023-10-28 ms4000001768031770 来自广东省

为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter，我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊

164 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务